Liver News and Research

RSS

Researchers discover how Fra-1 protein protects the liver from drug-induced liver damage

Drug abuse and alcohol are some of the most frequent causes of liver damage, particularly in developed countries. Such kind of liver damage can cause irreversible liver failure and even cancer. Researchers from the Spanish National Cancer Research Centre have discovered an important new protective role of the Fra-1 protein, which neutralizes the damage caused by agents, such as the analgesic drug acetaminophen (Paracetamol).

12 Oct 2013

Scientists develop new method to create stem cells for human liver and pancreas

A new method for creating stem cells for the human liver and pancreas, which could enable both cell types to be grown in sufficient quantities for clinical use, has been developed by scientists.

11 Oct 2013

Researchers find ways to identify, isolate HCC progenitor cells before tumors become evident

For the first time, researchers at the University of California, San Diego School of Medicine have isolated and characterized the progenitor cells that eventually give rise to malignant hepatocellular carcinoma tumors - the most common form of liver cancer. The researchers found ways to identify and isolate the HCC progenitor cells long before actual tumors were apparent.

11 Oct 2013

Adding danoprevir to treatment regimen for hepatitis C patients leads to high rates of remission

The addition of danoprevir to the current treatment regimen for patients with hepatitis C leads to high rates of remission, according to a new article in Gastroenterology, the official journal of the American Gastroenterological Association.

11 Oct 2013

Intravenous feeding can cause liver damage, say researchers

Researchers know that feeding some patients intravenously can save their lives - but also can cause liver damage. Now scientists at the University of Colorado and Children's Hospital Colorado have figured out the likely culprit, one of the ingredients in intravenous food, behind the liver problems.

10 Oct 2013

People with high amounts of abdominal fat are likely to develop memory loss

Although problems with memory become increasingly common as people age, in some persons, memories last long time, even a life time. On the other hand, some people experience milder to substantial memory problems even at an earlier age.

10 Oct 2013

Promedior starts Phase 2 clinical trial to evaluate PRM-151 in patients with myelofibrosis

Promedior, Inc., a clinical stage biotechnology company developing novel biologic therapeutics for the treatment of fibrosis, announced today that it has initiated a Phase 2 clinical trial to evaluate PRM-151, its lead product candidate, in patients with myelofibrosis.

10 Oct 2013

Studies suggest infusion of blood vessel cells may contribute to organ regeneration in future

Damaged or diseased organs may someday be healed with an injection of blood vessel cells, eliminating the need for donated organs and transplants, according to scientists at Weill Cornell Medical College.

9 Oct 2013

Researchers recently launched Collaborative Hepatitis Network in Africa

Although it does not receive as much attention as AIDS, hepatitis has long been one of Africa's most serious health problems.

9 Oct 2013

Healthcare providers report unaccompanied teens may not receive required vaccines

Healthcare providers report that older teens often go to the doctor without a parent or guardian, a new survey in the Journal of Adolescent Health reveals—and those teens may not get necessary vaccinations because there's no parent or guardian present to give consent.

9 Oct 2013

Janssen buys all rights from GSK to develop, commercialize hepatitis C compound

Janssen Pharmaceuticals, Inc. announced today the acquisition of the investigational compound GSK2336805, an NS5a replication complex inhibitor in Phase 2 development for the treatment of chronic hepatitis C, from an affiliate of GlaxoSmithKline plc.

9 Oct 2013

Sahlgrenska Academy study finds no traces of viruses in breast cancer and glioblastoma

A major study conducted at the Sahlgrenska Academy has now disproved theories of a viral cause for breast cancer and the brain tumour, glioblastoma. The study, which was based on over seven billion DNA sequences and which is published in Nature Communications, found no genetic traces of viruses in these forms of cancer.

9 Oct 2013

Retinitis pigmentosa test identifies mutation found in Ashkenazi Jewish population

You might not think to look to a urine test to diagnose an eye disease. But a new Duke University study says it can link what is in a patient's urine to gene mutations that cause retinitis pigmentosa, or RP, an inherited, degenerative disease that results in severe vision impairment and often blindness. The findings appear online in the Journal of Lipid Research.

9 Oct 2013

Alnylam advances Development Candidate for ALN-AS1 for treatment of hepatic porphyrias

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, announced today that it is advancing its Development Candidate for ALN-AS1, an RNAi therapeutic targeting aminolevulinate synthase-1 (ALAS-1) for the treatment of hepatic porphyrias including acute intermittent porphyria (AIP).

9 Oct 2013

Arrowhead initiates Phase 1 study of ARC-520 for treatment against chronic HBV infection

Arrowhead Research Corporation (NASDAQ: ARWR), a biopharmaceutical company developing targeted RNAi therapeutics, today announced that it completed enrollment in a Phase 1 clinical trial of ARC-520, its RNAi-based candidate against chronic hepatitis B virus infection.

9 Oct 2013

Acorda Therapeutics initiates second clinical trial of Glial Growth Factor 2 in heart failure patients

Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced that the first patient has been enrolled in the second clinical trial of Glial Growth Factor 2 (GGF2). This Phase 1b single-infusion trial in people with heart failure will assess tolerability of three dose levels of GGF2, and also includes several explorative measures of efficacy.

9 Oct 2013

Boehringer Ingelheim’s interim data from Phase II HCV clinical collaboration with Presidio Pharmaceuticals accepted for presentation at AASLD

Boehringer Ingelheim today announced that interim data from its Phase II hepatitis C (HCV) clinical collaboration with Presidio Pharmaceuticals have been accepted for presentation as a late breaker poster at the 64th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD), taking place 1-5 November in Washington, D.C. (1) The poster presentation will be on Monday 4 November.

8 Oct 2013

Liver News and Research

Researchers discover how Fra-1 protein protects the liver from drug-induced liver damage

Scientists develop new method to create stem cells for human liver and pancreas

Researchers find ways to identify, isolate HCC progenitor cells before tumors become evident

Adding danoprevir to treatment regimen for hepatitis C patients leads to high rates of remission

Intravenous feeding can cause liver damage, say researchers

People with high amounts of abdominal fat are likely to develop memory loss

Promedior starts Phase 2 clinical trial to evaluate PRM-151 in patients with myelofibrosis

Studies suggest infusion of blood vessel cells may contribute to organ regeneration in future

Researchers recently launched Collaborative Hepatitis Network in Africa

Healthcare providers report unaccompanied teens may not receive required vaccines

Janssen buys all rights from GSK to develop, commercialize hepatitis C compound

Sahlgrenska Academy study finds no traces of viruses in breast cancer and glioblastoma

Retinitis pigmentosa test identifies mutation found in Ashkenazi Jewish population

Alnylam advances Development Candidate for ALN-AS1 for treatment of hepatic porphyrias

Arrowhead initiates Phase 1 study of ARC-520 for treatment against chronic HBV infection

Acorda Therapeutics initiates second clinical trial of Glial Growth Factor 2 in heart failure patients

Boehringer Ingelheim’s interim data from Phase II HCV clinical collaboration with Presidio Pharmaceuticals accepted for presentation at AASLD

J&J's Janssen Buys Rights To Hepatitis C Compound From GSK

Metastatic site impacts survival in targeted RCC treatment

Surgeon finds way to perform laparoscopic gallbladder removal in Nicaragua

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News